Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Post by BornReady1970on Nov 12, 2009 10:53am
569 Views
Post# 16479394

Burn Rate

Burn RateWell it would appear from its financials that ISA has enough cash to last till Aug/Sep 2010. This should be long enough to achieve the Lux milestone payments, and while $10m isn't a game changer it should provide the company all it requires until the royalties start coming in. My gut tells me the royalties aren't going to make this company by themselves but I see two big positives out of the Lux deal:

First, ISA will have revenues, small as they may be they will have revenues and will thus be subject to some degree of multiples valuation, this can only help the share price.

Two, ISA will have a drug in the marketplace, the same drug they are trying to partner with for richer indications. I can't see anyway this hurts their efforts to find a partner to push forward with phase 3 trials in transplant, but I can see where it helps.

Looking forward to the official NDA anouncement.

Cheers,
BR
Bullboard Posts